RPN11 deubiquitinase promotes proliferation and migration of breast cancer cells

Abstract

The deubiquitinase enzyme RPN11 is involved in oncogenesis in various types of cancer. However, in breast cancer, the expression levels, prognostic relevance and biological function of RPN11 remains unclear. In the present study, RPN11 expression levels in breast cancer tissues and adjacent non‑tumor tissues were determined by reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining, and the association of RPN11 with clinicopathological features of breast cancer was evaluated. RPN11 expression was upregulated in breast cancer tissues compared with healthy tissues. Additionally, high expression levels of RPN11 may be an indicator of poor prognosis, as validated by a breast cancer cohort from the Gene Expression Omnibus database. Knockdown of RPN11 in MDA‑MB‑231 and T47D cells significantly reduced cell proliferation and enhanced G0/G1 arrest and apoptosis. Exogenous overexpression of RPN11 in MCF7 and Hs578T cells promoted cell growth and inhibited apoptosis. In addition, knockdown of RPN11 abrogated cell migration and reduced epithelial‑mesenchymal transition. In conclusion, these findings suggested that RPN11 may function as an oncogene and its upregulation in breast cancer suggests that it may be a therapeutic target.

Immune prognostic implications of PSMD14 and its associated genes signatures in hepatocellular carcinoma

“…We analyzed the correlation between seven prognostic genes (PSMD14, RBM45, PSMD1, OLA1, including HCC, esophageal cancer, breast cancer [5,[12][13]. Our results are in accordance with these studies, implying that PSMD14 could be a potential prognostic gene for HCC [5].…”

“…PSMD14 has been confirmed to play vital roles in gene ontology and related pathway, including protein stability [6], tumour formation [7], transcriptional regulation [8], double-strand DNA break repair [9], senescence [10], apoptosis and resistance [11], growth and metastasis [5], BMP6 signaling [6], TGF-β signaling [8]. Recently, PSMD14 has been overexpressed in many human cancers, such as HCC, colorectal cancer, multiple myeloma, esophageal squamous cell carcinoma and breast cancer, which it This is related to the poor prognosis of the patients [5,6,[11][12][13]. PSMD14 acts as an oncogene that promotes tumor progression by deubiquitinating of different protein substrates.…”

Upregulation of deubiquitinase PSMD14 in lung adenocarcinoma (LUAD) and its prognostic significance

“…PSMD14 is a deubiquitinating enzyme responsible for substrate deubiquitination during proteasomal degradation. Although the role of PSMD14 has been reported in several cancer types [17,19,21,22,25,34], its involvement in lung cancer has not been elucidated. In this study, we found that the level of PSMD14 was significantly upregulated in NSCLC tissues, suggesting its tumor-promoting effects in NSCLC.…”

“…PSMD14 is involved in a series of important physiological and pathological processes such as DNA damage repair [13][14][15][16], tumor formation [17][18][19], and inflammation [20]. PSMD14 promotes cell growth and proliferation of gliomas, colon cancer, liver cancer, esophageal cancer, and breast cancer, and enhances the resistance of tumor cells to radiation and Ivyspring International Publisher chemotherapy drugs [17][18][19][20][21][22][23]. Reduced PSMD14 expression inhibits tumor growth by inducing cell cycle arrest, senescence, or apoptosis.…”

“…Reduced PSMD14 expression inhibits tumor growth by inducing cell cycle arrest, senescence, or apoptosis. Previous studies have demonstrated that PSMD14 promotes tumor progression by regulating key anti-cancer proteins such as c-jun, p53, SNAIL, mTOR, and E2F1 [17][18][19][20][21][22]24]. Importantly, small molecule inhibitors targeting PSMD14 were shown to be prospects for potential clinical application [25][26][27][28].…”